However, for initial staging, evidence suggests that 68Ga-PSMA has improved sensitivity for the detection of nodal metastases with excellent specificity in patients with intermediate to high-risk prostate cancer with a detection of 68% of nodal disease and a specificity of 99.1% [65]. This evidence concerns the gene FOLH1 and prostate cancer.